Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) Receive the US FDA's Breakthrough Therapy Designation for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Shots:
- The US FDA’s BT designation is based on an ongoing P-II DESTINY-Lung01 study assessing Enhertu in 170 patients with HER2 mutant or HER2 overexpressing unresectable and m-nsq. NSCLC- progressed after one or more systemic therapies including CT- molecular targeted therapy or immunotherapy and data from P-I study- published in Cancer Discovery
- The overall safety and tolerability profile of Enhertu in the ongoing DESTINY-Lung01 study is consistent with the P-I study. This designation marks the third BT designation for Enhertu in the US and the fourth expedited regulatory designation received globally
- Enhertu is a HER2 directed ADC- received accelerated approval in the US & approval in Japan under the conditional early approval system for unresectable/ metastatic HER2 positive metastatic BC- prior treated with anti-HER2 based regimens
Click here to read full press release/ article
Ref: Businesswire | Image: AstraZenca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com